DIRS.INFO The most relevant business & tech news

☆ Ro CEO Zach Reitano talks new GLP-1 supply tracker
▼ + stars: | 2024-06-04 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailRo CEO Zach Reitano talks new GLP-1 supply trackerZach Reitano, Ro co-founder and CEO, joins 'Fast Money' to talk its new GLP-1 supply tracker as demand for weight loss drugs cause shortages.

Persons: Zach Reitano

Telehealth company Ro on Wednesday launched a new tracker to help patients find a popular class of weight loss and diabetes drugs called GLP-1s amid shortages of those treatments in the U.S. The supply tracker could be a valuable tool for many Americans scrambling to get their hands on GLP-1s, such as Novo Nordisk 's weight loss injection Wegovy and diabetes drug Ozempic. The tracker aims to make GLP-1 supply information more transparent and accessible for everyone, regardless of whether they are enrolled in any of Ro's programs. The tracker is an interactive tool that gives people real-time supply information by drug, dose size and pharmacy location. He added that opening up the tracker to everyone also makes it more likely for both Ro patients and people not enrolled in the company's programs to access GLP-1s.

Persons: Ro, Eli Lilly, Zachariah Reitano, Reitano Organizations: Wednesday, U.S, Novo Nordisk, U.S . Food, Drug Administration, CNBC Locations: U.S

In addition to Wegovy and Ozempic, the GLP-1 class includes Eli Lilly's highly popular weight loss drug Zepbound and diabetes treatment Mounjaro. VanGilder signed up nearly four years ago and started taking the weekly diabetes injection Ozempic specifically for weight loss. The big difference between Calibrate and prior weight loss efforts, VanGilder said, is that she doesn't feel like she's dieting. Calibrate is one of the only companies to regularly release reports detailing the results of its weight loss program. The federal Medicare program by law can't cover weight loss drugs unless the prescription is for another approved health benefit, such as diabetes or cardiovascular health.

Persons: Michael Siluk, Gray Beard, She'd, that's, Beard, wouldn't, She's, Ro, Goldman Sachs, Eli Lilly's, it's, Andrew Dudum, There's, Zachariah Reitano, Reitano, Wegovy, WeightWatchers, Gary Foster, Foster, Oprah Winfrey's, Kim Gradwell, Lee Smith, Jennifer VanGilder, she'd, Jenny Craig, VanGilder, I've, Kristin Baier, Rob MacNaughton, Ro's Reitano, we'd, Eli Lilly, Craig Primack, Primack, Hims, Dudum, We're Organizations: — Novo, UCG, Novo Nordisk, CNBC, Teladoc Health, World Health Organization, Food, WeightWatchers Clinic, Ursinus College, Asset Management Locations: Charlotte , North Carolina, U.S, Dudley , North Tyneside, Britain, Collegeville , Pennsylvania, Hims

☆ 3 titans will fight to dominate the market for Wegovy in 2024
▼ + stars: | 2023-12-27 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +5 min

Dozens of startups have jumped into the weight-loss market this year as weight-loss drugs, including Wegovy and Ozempic, have exploded in popularity. The few companies with enough money and brand recognition to stand up to Ozempic's distribution challenges — WeightWatchers, Noom, and Ro — can expect to compete for market dominance next year. But WeightWatchers signaled it's going all in on weight-loss drugs by launching its own behavioral program for patients on Ozempic in December. WeightWatchersLike WeightWatchers, Noom has remained staunchly in the weight-loss market since its 2008 launch. Ro launched its own program prescribing weight-loss drugs in January.

Persons: VCs, — WeightWatchers, Sari Kaganoff, WeightWatchers, it's, Sima Sistani, Noom, Ro, Zach Reitano, Kaganoff, Saeju Jeong, Sam Barnes, Aaron DeGagne Organizations: Business, Rock Health, Web, Getty, PitchBook Locations: Ozempic

☆ He Sold Burritos Out of His Apartment Window. Now He’s Running a $7 Billion Startup.
▼ + stars: | 2023-11-25 | by ( Julie Wernau | ) www.wsj.com time to read: 1 min

Pivot Point is a new Wall Street Journal feature in which executives reflect on the successes and setbacks of their careers. The first Pivot Point installment is here. Zach Reitano was the only one in his cohort of a dozen summer interns at Booz & Co. a decade ago who didn’t get a full-time job. The failure set him up to lead a $7 billion healthcare company.

Persons: Zach Reitano Organizations: Booz & Co

☆ A $7 billion startup wanted to build patient-friendly healthcare. Its bet on buzzy weight-loss drugs is testing that vision.
▼ + stars: | 2023-06-29 | by ( Blake Dodge | Rebecca Torrence | ) www.businessinsider.com time to read: +12 min

Patient complaints go beyond the Wegovy shortageKaitlyn's complaints echo an array of issues faced by other Ro patients seeking weight-loss drugs. The patients Insider interviewed asked to be identified by their first names to protect their privacy. In this chat log, a Ro weight-loss patient sends messages to the startup asking to cancel the program. Reitano told Insider that around 90% of Ro patients got a response within 24 hours. "Until these DTC companies generally start getting into the muck of healthcare, they're not going to have a material impact," Parker told Insider.

Persons: Ro, Zachariah Reitano, Reitano, Li Ran, Robyn Phelps, Kaitlyn, She'd, didn't, she's, couldn't, Max Kerwick, drugstores, Max, Ro's, aren't, hasn't, Florian Gaertner, it's, TJ Parker, they're, Parker Organizations: New York, Getty, Better Business Bureau, Nordisk, Better Business, CareMetx, Ro, TechCrunch Locations: Xinhua, New York, New York City

☆ How buzzy weight-loss drugs like Ozempic became the next craze in the hottest part of healthcare
▼ + stars: | 2023-03-14 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +7 min

Healthcare companies are launching programs left and right to prescribe trendy weight-loss drugs. And Ro, a startup that prescribes and sells products like Viagra and hair-loss pills to consumers, is going all in with a program it launched in January to prescribe the weight-loss drugs to patients online. CalibrateFirst developed to manage type 2 diabetes, GLP-1 medications regulate blood-sugar levels, which can help people curb cravings and feel fuller after eating. The weight-loss market for GLP-1 drugs is relatively new, and not everyone is on board. But for some companies, stepping into prescribing these new weight-loss medications seems to simply be the natural next step for growth.

☆ Why buzzy weight-loss drugs are the next craze for healthcare startups
▼ + stars: | 2023-03-13 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +7 min

Healthcare companies are launching programs left and right to prescribe trendy weight-loss drugs. And Ro, a startup that prescribes and sells products like Viagra and hair-loss pills to consumers, is going all in with a program it launched in January to prescribe the weight-loss drugs to patients online. Even startups like Noom, which quietly started a program prescribing GLP-1 medications, could stand to benefit from the drugs' popularity after a tumultuous year for the startup. The weight-loss market for GLP-1 drugs is relatively new, and not everyone is on board. But for some companies, stepping into prescribing these new weight-loss medications seems to simply be the natural next step for growth.

☆ New weight loss drugs trending with billionaires and celebrities are about to enter more American homes
▼ + stars: | 2023-01-20 | by ( Barbara Collins | ) www.cnbc.com time to read: +8 min

GLP-1s also have been found to help with weight loss as they make individuals who use them feel fuller for a longer period of time. Using GLP-1s drug injections for weight loss has become one of the latest ways some big names in the market are shedding extra pounds. That's why his company has launched a program to offer GLP-1 drugs and corresponding medical care to individuals struggling with obesity or weight loss issues. Pairing personalized coaching with GLP-1s is the key to effective weight loss treatment, Reitano said, and helping patients maximize their results. A new real-time approach to weight managementReitano said it should not be an either/or scenario involving diabetes management of weight loss and that will change over the next decade.

☆ Jim Cramer's top 10 things to watch in the market Friday: Google job cuts, Netflix delivers
▼ + stars: | 2023-01-20 | by ( Jim Cramer | ) www.cnbc.com time to read: +4 min

Salesforce (CRM) downgraded to market perform from outperform (hold from buy) at Cowen, which also cut its price target to $160 per share from $175. Barclays upgrades Ralph Lauren (RL) to overweight from equal weight (buy from hold); increases its price target to $134 per share from $101. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Search resuls for: "Reitano"

10 mentions found